Taken together, targeting TXNDC5 may build a new avenue for liver fibrosis/cirrhosis treatments via blocking HSC activation, proliferation, ECM production, as well as depriving anti-apoptotic capacity of HSCs. The gene discussed is TXNDC5; the disease is Hepatic fibrosis.